MR-146 for Neurotrophic Keratopathy
(MR-146 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The objective of this study is to evaluate the safety, tolerability, and biologically effective dose (BED) of MR-146 for the treatment of Stage 1 and Stage 2 Neurotrophic Keratopathy (NK)
Are You a Good Fit for This Trial?
This trial is for people diagnosed with stage 1 or stage 2 neurotrophic keratopathy, a rare eye disease that affects the cornea. Participants must meet specific medical criteria set by the study and cannot join if they have certain other health conditions.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- MR-146
Trial Overview
The study is testing different single doses of MR-146, an experimental treatment, to find out how safe it is and what dose works best for treating early-stage neurotrophic keratopathy. The trial has two parts: one open-label and one double-masked.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
participants will receive a single mid-level dose of MR-146 administered via an intralacrimal gland injection
participants will receive a single high dose of MR-146 administered via an intralacrimal gland injection
Participants will receive a single low dose of MR-146 administered via an intralacrimal gland injection
Find a Clinic Near You
Who Is Running the Clinical Trial?
Viatris Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.